Key result
In 87 patients with rotator cuff defects, application of 2cc Wharton's Jelly allograft resulted in statistically significant improvements in patient-reported pain scales at 90 days.
Why the study?
With the increasing occurrence of rotator cuff injuries, there is a great need for a reliable treatment option.
Does Wharton's Jelly flowable allograft improve patient-reported pain scales in patients with rotator cuff defects who failed conservative treatment?
Cohort (n=87)
Does Wharton's Jelly flowable allograft improve patient-reported pain scales in patients with rotator cuff defects who failed conservative treatment?
Wharton's Jelly flowable allograft significantly improves patient-reported pain at 90 days in patients with rotator cuff defects refractory to conservative treatment.
May support allograft use for refractory rotator cuff pain; leaves open confirmation in randomized trials.
With the increasing occurrence of rotator cuff injuries every year, there is a great need for a reliable treatment option. Wharton’s Jelly contains several components that can positively impact the replacement and repair of musculoskeletal defects. The overall objective of this study is to evaluate the improvement of patient-reported pain scales after applying Wharton’s Jelly (WJ) in rotator cuff defects. Eighty-seven patients with rotator cuff defects who failed at least eight weeks of conservative treatment were selected from the retrospective repository. 2cc of WJ flowable allograft was applied to the specific affected anatomy, the most common being supraspinatus tendon, biceps tendon insertion, labral tear, and subscapularis tear. Patients were monitored for 30 minutes post-procedure. No adverse reactions were reported. Statistically significant improvements were found from initial to Day 90 for all pain scales used. No statistically significant differences were found in mean changes between gender, BMI, and age. Scanning Electron Microscopy images reveal the similarities between the collagen matrix in WJ and the rotator cuff. The significant improvement in patient outcomes coincides with current literature analyzing WJ applications with other structural defects around the body. WJ is a promising alternative for musculoskeletal defects when the standard of care fails.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2024) conducted a cohort in Rotator cuff defects (n=87). Wharton's Jelly flowable allograft was evaluated on Improvement of patient-reported pain scales. In 87 patients with rotator cuff defects, application of 2cc Wharton's Jelly allograft resulted in statistically significant improvements in patient-reported pain scales at 90 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: